PCAC July 2026 meeting: what the advisory committee is reviewing
The FDA's Pharmacy Compounding Advisory Committee convenes in July 2026. Here is what it does, what is on the agenda, and why the outcome matters.
TL;DR
- PCAC is the FDA advisory body that reviews which substances compounding pharmacies are allowed to use.
- In 2026, the committee is expected to evaluate evidence on peptides currently restricted under Category 2 classification.
- A PCAC recommendation is not a final rule — formal access changes require a Federal Register notice from FDA.
What the PCAC is
The Pharmacy Compounding Advisory Committee (PCAC) is an FDA advisory panel. It reviews scientific and policy questions about which drugs and substances compounding pharmacies may legally prepare. Think of it as a jury that weighs the evidence — FDA then decides what to do with the verdict.
The committee evaluates substances placed on the bulk drug substances lists under the Drug Quality and Security Act (DQSA) of 2013 (FDA, Drug Quality and Security Act framework, 2013). For peptides, this process has shaped access to compounds like BPC-157, TB-500, and others since 2023.
How the review process works
PCAC meetings follow a structured format. Researchers, clinicians, and pharmacy stakeholders present data. Committee members deliberate and vote on whether a substance presents sufficient clinical need and safety evidence to remain available through compounding.
A positive recommendation does not restore access immediately. It signals to FDA that the evidence supports reclassification. The formal step — a Federal Register notice — must still follow. That process can take months.
Who watches the PCAC closely
People come to this topic when they are waiting on a peptide that is currently restricted. Clinicians, compounding pharmacists, and patients tracking whether a Category 2 substance might regain Category 1 status monitor each PCAC meeting for signals.
The July 2026 session matters because an HHS announcement in early 2026 proposed returning certain peptides to Category 1 access, pending formal action. The committee meeting is one step in that process.
What the research base looks like
The PCAC weighs published literature — including peer-reviewed clinical studies, preclinical data, and post-market surveillance — against evidence of clinical need. For peptides under review, the research base is largely preclinical or small-scale human studies, which is why the committee process exists: to set a threshold for how much evidence is enough.
What to know before drawing conclusions
PCAC recommendations are non-binding. FDA is not obligated to act on them, and timelines slip. Any compound under review remains restricted until a Federal Register notice changes its status. Clinicians and patients should not assume access is restored until that step completes.
The Halftime POV
At Halftime Health, we follow each PCAC cycle closely — not because we expect overnight changes, but because the regulatory trajectory shapes what responsible clinical access looks like over time. We only prescribe through licensed clinicians in states where our partner physicians are credentialed, and we update our formulary when rules change, not in anticipation of them.
Related reading:
- PCAC advisory committee explained
- FDA reclassification April 2026 explained
- Why some peptides are still Category 2
- BPC-157 availability in 2026
- Peptide regulatory landscape 2026
FAQ
Q: What is the PCAC advisory committee? A: PCAC stands for the Pharmacy Compounding Advisory Committee. It is an FDA advisory body that reviews scientific and policy questions about drug compounding, including which substances belong on the Category 1 (permissible) or Category 2 (restricted) compounding lists.
Q: What does PCAC review in 2026? A: In 2026, PCAC is expected to weigh evidence on several peptides whose Category 2 status is under review following an HHS announcement in early 2026. The committee's guidance shapes whether those compounds can be compounded again under 503A pharmacy rules.
Q: Will peptides be reclassified in 2026? A: A formal reclassification requires an FDA Federal Register notice after the advisory process concludes. The PCAC meeting generates a recommendation, not a final rule. Timelines can shift, and no outcome is guaranteed until the Federal Register notice publishes.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- FDA — Pharmacy Compounding Advisory Committee (2024)
- FDA — Drug Quality and Security Act, Compounding (2013)
Frequently asked questions
what is the PCAC advisory committee
PCAC stands for the Pharmacy Compounding Advisory Committee. It is an FDA advisory body that reviews scientific and policy questions about drug compounding, including which substances belong on the Category 1 (permissible) or Category 2 (restricted) compounding lists.
what does PCAC review in 2026
In 2026, PCAC is expected to weigh evidence on several peptides whose Category 2 status is under review following an HHS announcement in early 2026. The committee's guidance shapes whether those compounds can be compounded again under 503A pharmacy rules.
will peptides be reclassified in 2026
A formal reclassification requires an FDA Federal Register notice after the advisory process concludes. The PCAC meeting generates a recommendation, not a final rule. Timelines can shift, and no outcome is guaranteed until the Federal Register notice publishes.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.